Hospitalization-related bone loss and the protective effect of risedronate View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-08-23

AUTHORS

Robert P. Heaney, David J. Valent, Ian P. Barton

ABSTRACT

Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean ± SEM) across the period of hospitalization was −0.65±0.39 at lumbar spine, −1.13±0.55 at femoral neck, and −2.66±0.58 at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46±0.28, −0.77±0.34, and −0.67±0.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter ( P =0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5 mg/day effectively abolished this loss. More... »

PAGES

212-216

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-005-1975-4

DOI

http://dx.doi.org/10.1007/s00198-005-1975-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032445349

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16133644


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Resorption", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etidronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Femur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lumbar Vertebrae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risedronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Creighton University, 601\u00a0N. 30th St., Suite 4841, 68131, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/grid.254748.8", 
          "name": [
            "Creighton University, 601\u00a0N. 30th St., Suite 4841, 68131, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heaney", 
        "givenName": "Robert P.", 
        "id": "sg:person.0645437522.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645437522.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.418758.7", 
          "name": [
            "Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valent", 
        "givenName": "David J.", 
        "id": "sg:person.0623324451.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623324451.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.418758.7", 
          "name": [
            "Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barton", 
        "givenName": "Ian P.", 
        "id": "sg:person.0610716744.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610716744.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001980050010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005303812", 
          "https://doi.org/10.1007/s001980050010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-002-1022-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031806066", 
          "https://doi.org/10.1007/s00223-002-1022-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-08-23", 
    "datePublishedReg": "2005-08-23", 
    "description": "Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean \u00b1 SEM) across the period of hospitalization was \u22120.65\u00b10.39\u00a0at lumbar spine, \u22121.13\u00b10.55\u00a0at femoral neck, and \u22122.66\u00b10.58\u00a0at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46\u00b10.28, \u22120.77\u00b10.34, and \u22120.67\u00b10.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter ( P =0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5\u00a0mg/day effectively abolished this loss.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-005-1975-4", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "serious adverse events", 
      "bone loss", 
      "intercurrent illness", 
      "femoral trochanter", 
      "lumbar spine", 
      "bone mineral density changes", 
      "age-related bone loss", 
      "placebo-treated participants", 
      "rapid bone loss", 
      "phase III trials", 
      "period of hospitalization", 
      "episodes of hospitalization", 
      "non-skin cancer", 
      "mineral density changes", 
      "important bone loss", 
      "non-hospitalized participants", 
      "period of illness", 
      "age-related loss", 
      "antiresorptive therapy", 
      "III trials", 
      "adverse events", 
      "cerebrovascular accident", 
      "prevalent fractures", 
      "gallbladder disease", 
      "hospitalized subjects", 
      "myocardial infarction", 
      "femoral neck", 
      "control subjects", 
      "placebo control", 
      "bone gain", 
      "retrospective analysis", 
      "protective effect", 
      "hospitalization", 
      "BMD data", 
      "percent change", 
      "illness", 
      "spine", 
      "significant differences", 
      "trochanter", 
      "subjects", 
      "participants", 
      "pneumonia", 
      "infarction", 
      "pancreatitis", 
      "surgery", 
      "risedronate", 
      "therapy", 
      "BMD", 
      "cancer", 
      "hip", 
      "disease", 
      "neck", 
      "dose", 
      "trials", 
      "loss", 
      "age", 
      "period", 
      "episodes", 
      "days", 
      "fractures", 
      "corresponding values", 
      "population", 
      "changes", 
      "interval", 
      "differences", 
      "weight", 
      "control", 
      "sites", 
      "study", 
      "events", 
      "contrast", 
      "accidents", 
      "effect", 
      "density changes", 
      "hypothesis", 
      "objective", 
      "data", 
      "values", 
      "time", 
      "gain", 
      "analysis", 
      "same time", 
      "height", 
      "magnitude"
    ], 
    "name": "Hospitalization-related bone loss and the protective effect of risedronate", 
    "pagination": "212-216", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032445349"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-005-1975-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16133644"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-005-1975-4", 
      "https://app.dimensions.ai/details/publication/pub.1032445349"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_409.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-005-1975-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-005-1975-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-005-1975-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-005-1975-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-005-1975-4'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      21 PREDICATES      126 URIs      116 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-005-1975-4 schema:about N08cb96e1f2c8458f8eccbc65f3d4f9c0
2 N12bfdda479084135b7f21c83b1e84ad2
3 N358ee32c1c7040f4944ae55c484f7e59
4 N4821d80573a6468d9306b8eb94875f03
5 N5531ddd4793241aea0195ab525ec0dcc
6 N5fef9ae03b174308b46fde1065288b83
7 N73cfeb3218134f33a6b512fe12fa49c8
8 N756c794cb7904c52860831f309b0bc31
9 N8bf70934f7604954864c71b4399d5ffd
10 N91cbd4c5965c4322a31585a2e7c2e56c
11 N94a93d43c6cc4098aab6234b0748322d
12 Nab899bd6460e437bb8f6d04e4c6a413f
13 Nd1249892110a427394659b3e5d08722f
14 Ne4f49dbeec5946569235c2dbcf095607
15 Neb9bbb313fd547149cd58031b6046144
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N6a6afe35c56f4a3bb1adb0cff99715c1
19 schema:citation sg:pub.10.1007/s001980050010
20 sg:pub.10.1007/s00223-002-1022-9
21 schema:datePublished 2005-08-23
22 schema:datePublishedReg 2005-08-23
23 schema:description Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean ± SEM) across the period of hospitalization was −0.65±0.39 at lumbar spine, −1.13±0.55 at femoral neck, and −2.66±0.58 at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46±0.28, −0.77±0.34, and −0.67±0.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter ( P =0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5 mg/day effectively abolished this loss.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N3c51ddceee674e5e90fd01bda71aec8e
27 N4cb880f4f1944daf9389643650df031d
28 sg:journal.1100834
29 schema:keywords BMD
30 BMD data
31 III trials
32 accidents
33 adverse events
34 age
35 age-related bone loss
36 age-related loss
37 analysis
38 antiresorptive therapy
39 bone gain
40 bone loss
41 bone mineral density changes
42 cancer
43 cerebrovascular accident
44 changes
45 contrast
46 control
47 control subjects
48 corresponding values
49 data
50 days
51 density changes
52 differences
53 disease
54 dose
55 effect
56 episodes
57 episodes of hospitalization
58 events
59 femoral neck
60 femoral trochanter
61 fractures
62 gain
63 gallbladder disease
64 height
65 hip
66 hospitalization
67 hospitalized subjects
68 hypothesis
69 illness
70 important bone loss
71 infarction
72 intercurrent illness
73 interval
74 loss
75 lumbar spine
76 magnitude
77 mineral density changes
78 myocardial infarction
79 neck
80 non-hospitalized participants
81 non-skin cancer
82 objective
83 pancreatitis
84 participants
85 percent change
86 period
87 period of hospitalization
88 period of illness
89 phase III trials
90 placebo control
91 placebo-treated participants
92 pneumonia
93 population
94 prevalent fractures
95 protective effect
96 rapid bone loss
97 retrospective analysis
98 risedronate
99 same time
100 serious adverse events
101 significant differences
102 sites
103 spine
104 study
105 subjects
106 surgery
107 therapy
108 time
109 trials
110 trochanter
111 values
112 weight
113 schema:name Hospitalization-related bone loss and the protective effect of risedronate
114 schema:pagination 212-216
115 schema:productId N3b42ca96171043539fe85f96ab31231e
116 Na831b5b84a0741d6a5c5c4d2dc47922c
117 Nd10b67ddef1d40a7a91f9e46ef528362
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032445349
119 https://doi.org/10.1007/s00198-005-1975-4
120 schema:sdDatePublished 2022-08-04T16:55
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N994720ca0f394b3c88c7643e2cad010e
123 schema:url https://doi.org/10.1007/s00198-005-1975-4
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N08cb96e1f2c8458f8eccbc65f3d4f9c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Etidronic Acid
129 rdf:type schema:DefinedTerm
130 N12bfdda479084135b7f21c83b1e84ad2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Bone Resorption
132 rdf:type schema:DefinedTerm
133 N1352b8a90f85461bb4ca14714079d7d8 rdf:first sg:person.0623324451.17
134 rdf:rest N6c47e5adb31342c2bbb500ba1c024413
135 N358ee32c1c7040f4944ae55c484f7e59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Femur
137 rdf:type schema:DefinedTerm
138 N3b42ca96171043539fe85f96ab31231e schema:name doi
139 schema:value 10.1007/s00198-005-1975-4
140 rdf:type schema:PropertyValue
141 N3c51ddceee674e5e90fd01bda71aec8e schema:issueNumber 2
142 rdf:type schema:PublicationIssue
143 N4821d80573a6468d9306b8eb94875f03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Lumbar Vertebrae
145 rdf:type schema:DefinedTerm
146 N4cb880f4f1944daf9389643650df031d schema:volumeNumber 17
147 rdf:type schema:PublicationVolume
148 N5531ddd4793241aea0195ab525ec0dcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Osteoporosis
150 rdf:type schema:DefinedTerm
151 N5fef9ae03b174308b46fde1065288b83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Bone Density
153 rdf:type schema:DefinedTerm
154 N6a6afe35c56f4a3bb1adb0cff99715c1 rdf:first sg:person.0645437522.96
155 rdf:rest N1352b8a90f85461bb4ca14714079d7d8
156 N6c47e5adb31342c2bbb500ba1c024413 rdf:first sg:person.0610716744.05
157 rdf:rest rdf:nil
158 N73cfeb3218134f33a6b512fe12fa49c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Osteoporosis, Postmenopausal
160 rdf:type schema:DefinedTerm
161 N756c794cb7904c52860831f309b0bc31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Humans
163 rdf:type schema:DefinedTerm
164 N8bf70934f7604954864c71b4399d5ffd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Retrospective Studies
166 rdf:type schema:DefinedTerm
167 N91cbd4c5965c4322a31585a2e7c2e56c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Bone Density Conservation Agents
169 rdf:type schema:DefinedTerm
170 N94a93d43c6cc4098aab6234b0748322d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Aged
172 rdf:type schema:DefinedTerm
173 N994720ca0f394b3c88c7643e2cad010e schema:name Springer Nature - SN SciGraph project
174 rdf:type schema:Organization
175 Na831b5b84a0741d6a5c5c4d2dc47922c schema:name dimensions_id
176 schema:value pub.1032445349
177 rdf:type schema:PropertyValue
178 Nab899bd6460e437bb8f6d04e4c6a413f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Risedronic Acid
180 rdf:type schema:DefinedTerm
181 Nd10b67ddef1d40a7a91f9e46ef528362 schema:name pubmed_id
182 schema:value 16133644
183 rdf:type schema:PropertyValue
184 Nd1249892110a427394659b3e5d08722f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Female
186 rdf:type schema:DefinedTerm
187 Ne4f49dbeec5946569235c2dbcf095607 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Hospitalization
189 rdf:type schema:DefinedTerm
190 Neb9bbb313fd547149cd58031b6046144 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Treatment Outcome
192 rdf:type schema:DefinedTerm
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
197 schema:name Clinical Sciences
198 rdf:type schema:DefinedTerm
199 sg:journal.1100834 schema:issn 0937-941X
200 1433-2965
201 schema:name Osteoporosis International
202 schema:publisher Springer Nature
203 rdf:type schema:Periodical
204 sg:person.0610716744.05 schema:affiliation grid-institutes:grid.418758.7
205 schema:familyName Barton
206 schema:givenName Ian P.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610716744.05
208 rdf:type schema:Person
209 sg:person.0623324451.17 schema:affiliation grid-institutes:grid.418758.7
210 schema:familyName Valent
211 schema:givenName David J.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623324451.17
213 rdf:type schema:Person
214 sg:person.0645437522.96 schema:affiliation grid-institutes:grid.254748.8
215 schema:familyName Heaney
216 schema:givenName Robert P.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645437522.96
218 rdf:type schema:Person
219 sg:pub.10.1007/s001980050010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005303812
220 https://doi.org/10.1007/s001980050010
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/s00223-002-1022-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031806066
223 https://doi.org/10.1007/s00223-002-1022-9
224 rdf:type schema:CreativeWork
225 grid-institutes:grid.254748.8 schema:alternateName Creighton University, 601 N. 30th St., Suite 4841, 68131, Omaha, NE, USA
226 schema:name Creighton University, 601 N. 30th St., Suite 4841, 68131, Omaha, NE, USA
227 rdf:type schema:Organization
228 grid-institutes:grid.418758.7 schema:alternateName Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA
229 schema:name Procter and Gamble Pharmaceuticals, Cincinnati, OH, USA
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...